Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00286182 · ClinicalTrials.gov registry record · Phase 2
Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)
A Phase 2 study of Anemia, sponsored by Mathew S. Maurer.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT00286182: Completed Phase 2 study of Anemia, sponsored by Mathew S. Maurer.
NCT00286182 is a Phase 2 study of Anemia that has completed, run by Mathew S. Maurer. The registered enrollment target is 56 participants, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00286182, a Phase 2 study of Anemia, has completed, sponsored by Mathew S. Maurer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if treating anemia with subcutaneous erythropoetin in patients with heart failure and a preserved ejection fraction (HFPEF) will be associated with reverse ventricular remodeling, significant improvements in exercise capacity, and improved health status, as compared with placebo.
Primary Outcome
This outcome measure is collected using a three dimensional echocardiography.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Erythropoietin alpha
Study Locations (1)
New York
- Clinical Cardiovascular Research Laboratory for the Elderly - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2007-07 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
What the finished NCT00286182 record still lists
NCT00286182 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Anemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00286182 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00286182 about?
NCT00286182 is a clinical study titled "Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)". The purpose of this study is to determine if treating anemia with subcutaneous erythropoetin in patients with heart failure and a preserved ejection fraction (HFPEF) will be associated with reverse ventricular remodeling, significant improvements in exercise capacity, and improved health status, as ...
What is the current status of trial NCT00286182?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2007-07. Estimated completion is 2012-11.
What conditions does trial NCT00286182 study?
This clinical trial studies the following conditions: Anemia.
What interventions are being tested in trial NCT00286182?
The interventions under investigation include: Placebo (DRUG), Erythropoietin alpha (DRUG).
Who is sponsoring clinical trial NCT00286182?
This trial is sponsored by Mathew S. Maurer, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00286182 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00286182's enrollment target sits among peer trials
56 56th of 72 higher than 17 of 72 other Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
Study of DISC-0974-201 in Participants With IBD and Anemia
RECRUITING · Phase 2
-
129Xe MRI Cardiopulmonary
RECRUITING · Phase 2
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Choline and Iron Deficiency
RECRUITING · Phase 2
-
Luspatercept for Clonal Cytopenias of Uncertain Significance
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia